WHO – Page 11 – Pharma.Tips

Inspection responses delayed during post-inspection response – preventing escalation to warning letter

Strategies to Address Delayed Responses in Post-Inspection Phases to Prevent Escalation to Warning Letters In the ever-evolving landscape of pharmaceutical manufacturing and quality assurance, timely responses to inspection findings are…

CAPA follow-up weak before regulatory inspection – preventing escalation to warning letter

Strengthening CAPA Follow-Up Protocols Before Regulatory Inspections In the pharmaceutical manufacturing landscape, poor CAPA (Corrective and Preventive Action) follow-up can lead to significant compliance issues, particularly before regulatory inspections. To…

Inspection readiness untested during WHO audit – evidence pack inspectors expect

Practical Playbook for Ensuring Inspection Readiness During WHO Audits In the pharmaceutical industry, the possibility of audits from the World Health Organization (WHO) can create significant anxiety regarding inspection readiness…

Inspection responses delayed during remediation tracking – preventing escalation to warning letter

Resolving Delayed Inspection Responses During Remediation Tracking to Avoid Escalation In the pharmaceutical manufacturing landscape, the timely response during remediation tracking is critical to maintaining compliance and avoiding regulatory citations.…

Team unprepared for interviews during FDA/EMA inspection – inspection playbook and preparation strategy

Preparing Your Team for Successful Interviews During FDA and EMA Inspections In the highly regulated pharmaceutical industry, regulatory inspections are critical checkpoints to ensure compliance with Good Manufacturing Practices (GMP).…

CAPA follow-up weak before regulatory inspection – CAPA closure verification

Addressing Deficiencies in CAPA Follow-Up Prior to Regulatory Inspections In pharmaceutical manufacturing, efficient Corrective and Preventive Actions (CAPA) are crucial for maintaining compliance with Good Manufacturing Practices (GMP) and preparing…

Inspection readiness untested during FDA/EMA inspection – inspection playbook and preparation strategy

Practical Guide to Enhancing Inspection Readiness for FDA and EMA Audits The pharmaceutical industry faces constant scrutiny from regulatory bodies such as the FDA and EMA, and inspection readiness is…

Inspection readiness untested during FDA/EMA inspection – inspection playbook and preparation strategy

Preparing for FDA/EMA Inspections: A Comprehensive Playbook for Inspection Readiness Pharmaceutical manufacturers are regularly subject to inspections by regulatory bodies such as the FDA, EMA, and MHRA. Many times, the…

Mock audit findings ignored during FDA/EMA inspection – evidence pack inspectors expect

How to Address Mock Audit Findings Before FDA/EMA Inspections During pharmaceutical manufacturing, the gap between passing a mock audit and facing an actual FDA or EMA inspection can often reveal…

CAPA follow-up weak during remediation tracking – evidence pack inspectors expect

Strengthening CAPA Follow-Up During Remediation Tracking for Inspection Readiness In pharmaceutical manufacturing, a strong Corrective and Preventive Action (CAPA) process is crucial for maintaining compliance with Good Manufacturing Practice (GMP)…

Mock audit findings ignored during FDA/EMA inspection – preventing escalation to warning letter

How to Address Mock Audit Findings Before FDA/EMA Inspections to Prevent Warning Letters In the pharmaceutical industry, the stakes are high when regulatory inspections occur. This article focuses on a…

Inadequate evidence during inspection during FDA/EMA inspection – preventing escalation to warning letter

Mitigating Inadequate Evidence During FDA/EMA Inspections to Prevent Escalation Pharmaceutical manufacturing organizations frequently find themselves navigating rigorous FDA and EMA inspections, where the adequacy of evidence can determine the trajectory…